Claudio Bravo Carillo, MD

Title(s)HS Assoc Clinical Professor, Medicine
SchoolSchool of Medicine
ORCID ORCID Icon0000-0002-7561-052X Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    Universidad Católica de la Santísima Concepción, Concepcion, ChileMD2008Medicine
    Rutgers University, New Jersey, USA2013Post-doctoral Fellowship
    Bridgeport Hospital-Yale University, Connecticut, USA2016Internal Medicine
    Montefiore Medical Center-Albert Einstein School of Medicine, New York, USA2019Cardiology
    New York Presbyterian Hospital-Columbia University, New York, USA2020Advanced Heart Failure and Transplant
    University of Washington, Washington, USAMSc2023Master of Science - Epidemiology

    Collapse Overview 
    Collapse overview
    Dr. Claudio Bravo, MSc, FACC, FESC, FAHA, is a physician-scientist and currently an Associate Professor of Medicine and a heart failure and transplant cardiologist at UCSF. He completed fellowship training in Advanced Heart Failure and Transplant Cardiology at Columbia University and holds a Master of Science in Epidemiology from the University of Washington. His primary contributions include describing the role of adenylyl cyclase type 5 blockade in animal models of heart failure and studying outcomes of patients with advanced heart failure using continuous flow LVADs. His research focuses on discovering new molecular mechanisms and pharmacological targets for treating right ventricular failure using multi-omics. Clinically, Dr. Bravo's goal is to provide top-notch medical care to his patients and to advance the field.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Société de Biomécanique Young Investigator Award: In silico study of the effects of Left Ventricular Assist Device inflow cannula design and pump unsteady flow on left ventricular hemodynamics. J Biomech. 2025 Jul 16; 190:112870. Chassagne F, Léger C, Straccia A, Bravo CA, Beckman JA, Li S, Mahr C, Aliseda A. PMID: 40729897.
      View in: PubMed   Mentions:
    2. Heart transplantation outcomes with donation after circulatory death in patients with left ventricular assist device. ESC Heart Fail. 2025 Jun 26. Karatasakis A, Silvestri EG, Nair GG, Zuniga B, Li S, Mahr C, Cheng RK, Stempien-Otero AS, Dimarakis I, Khorsandi M, Pal JD, Kizer JR, Simon MA, Bravo CA. PMID: 40574369.
      View in: PubMed   Mentions:
    3. Percutaneous Assessment and Intervention of Outflow Graft Stenosis in Left Ventricular Assist Device Patients-A Cohort Study. ASAIO J. 2025 Mar 25. Bravo CA, Chassagne F, Aliseda A, Beckman JA, Li S, Mahr C. PMID: 40178531.
      View in: PubMed   Mentions:
    4. Proteomic Signatures of Right Ventricular Outcomes in Pulmonary Arterial Hypertension. Circ Heart Fail. 2024 Nov; 17(11):e012067. Pi H, Xia L, Boucherat O, Suresh K, Hemnes AR, Bonnet S, Bravo CA, Oppegard L, Rayner SG, Shojaie A, Gharib SA, Leary PJ. PMID: 39435559; PMCID: PMC11576243.
      View in: PubMed   Mentions:
    5. The Impact of the 2018 Allocation System Change on Patients Bridged With Durable Left Ventricular Assist Device: An Updated UNOS Registry Analysis. ASAIO J. 2024 May 01; 70(5):456-459. Braghieri L, Olivas-Martinez A, Silvestri EG, Karatasakis A, Li S, Mahr C, Bravo C. PMID: 38207111.
      View in: PubMed   Mentions:
    6. Pathophysiology and management of valvular disease in patients with destination left ventricular assist devices. Front Cardiovasc Med. 2022; 9:1029825. Dimarakis I, Callan P, Khorsandi M, Pal JD, Bravo CA, Mahr C, Keenan JE. PMID: 36407458; PMCID: PMC9669306.
      View in: PubMed   Mentions:
    7. Explainable Machine Learning Analysis of Right Heart Failure After Left Ventricular Assist Device Implantation. ASAIO J. 2023 May 01; 69(5):417-423. Bahl A, Qureshi B, Zhang K, Bravo C, Mahr C, Li S. PMID: 36730914.
      View in: PubMed   Mentions:
    8. Right heart failure after left ventricular assist device: From mechanisms to treatments. Front Cardiovasc Med. 2022; 9:1023549. Bravo CA, Navarro AG, Dhaliwal KK, Khorsandi M, Keenan JE, Mudigonda P, O'Brien KD, Mahr C. PMID: 36337897; PMCID: PMC9626829.
      View in: PubMed   Mentions:
    9. The History of Durable Left Ventricular Assist Devices and Comparison of Outcomes: HeartWare, HeartMate II, HeartMate 3, and the Future of Mechanical Circulatory Support. J Clin Med. 2022 Apr 05; 11(7). Berardi C, Bravo CA, Li S, Khorsandi M, Keenan JE, Auld J, Rockom S, Beckman JA, Mahr C. PMID: 35407630; PMCID: PMC9000165.
      View in: PubMed   Mentions:
    10. Systematic Assessment of Online Health Information for Coronary Revascularization. JAMA Intern Med. 2021 Jul 01; 181(7):1003-1006. Hameed I, Hameed NUF, Oakley CT, Gambardella I, Bravo C, Angiolillo DJ, Gaudino M. PMID: 33871563; PMCID: PMC8056308.
      View in: PubMed   Mentions:
    11. Presence of Intracardiac Thrombus at the Time of Left Ventricular Assist Device Implantation Is Associated With an Increased Risk of Stroke and Death. J Card Fail. 2021 Dec; 27(12):1367-1373. Bravo CA, Fried JA, Willey JZ, Javaid A, Mondellini GM, Braghieri L, Lumish H, Topkara VK, Kaku Y, Witer L, Takayama H, Takeda K, Sayer G, Uriel N, Demmer RT, Naka Y, Yuzefpolskaya M, Colombo PC. PMID: 34161806; PMCID: PMC8865378.
      View in: PubMed   Mentions:
    12. Systematic Review of the Association Between Worsening Renal Function and Mortality in Patients With Acute Decompensated Heart Failure. Kidney Int Rep. 2020 Sep; 5(9):1486-1494. Yamada T, Ueyama H, Chopra N, Yamaji T, Azushima K, Kobayashi R, Kinguchi S, Urate S, Suzuki T, Abe E, Saigusa Y, Wakui H, Partridge P, Burger A, Bravo CA, Rodriguez MA, Ivey-Miranda J, Tamura K, Testani J, Coca S. PMID: 32954072; PMCID: PMC7486197.
      View in: PubMed   Mentions:
    13. Metabolomic Profiling of Left Ventricular Diastolic Dysfunction in Women With or at Risk for HIV Infection: The Women's Interagency HIV Study. J Am Heart Assoc. 2020 02 18; 9(4):e013522. Bravo CA, Hua S, Deik A, Lazar J, Hanna DB, Scott J, Chai JC, Kaplan RC, Anastos K, Robles OA, Clish CB, Kizer JR, Qi Q. PMID: 32063116; PMCID: PMC7070185.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    14. Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: A systematic review and meta-analysis. Vascular. 2019 Feb; 27(1):78-89. Olmedo W, Villablanca PA, Sanina C, Walker J, Weinreich M, Brevik J, Avendano R, Bravo CA, Romero J, Ramakrishna H, Babaev A, Attubato M, Hernandez-Suarez DF, Cox-Alomar P, Pyo R, Krishnan P, Wiley J. PMID: 30501582.
      View in: PubMed   Mentions:
    15. Meta-Analysis and Trial Sequential Analysis Comparing Percutaneous Ventricular Assist Devices Versus Intra-Aortic Balloon Pump During High-Risk Percutaneous Coronary Intervention or Cardiogenic Shock. Am J Cardiol. 2018 Oct 15; 122(8):1330-1338. Rios SA, Bravo CA, Weinreich M, Olmedo W, Villablanca P, Villela MA, Ramakrishna H, Hirji S, Robles OA, Mahato P, Gluud C, Bhatt DL, Jorde UP. PMID: 30146099.
      View in: PubMed   Mentions:
    16. A novel adenylyl cyclase type 5 inhibitor that reduces myocardial infarct size even when administered after coronary artery reperfusion. J Mol Cell Cardiol. 2018 Aug; 121:13-15. Zhang J, Levy D, Oydanich M, Bravo CA, Yoon S, Vatner DE, Vatner SF. PMID: 29800555; PMCID: PMC6103820.
      View in: PubMed   Mentions:
    17. Cochrane corner: complete versus culprit-only revascularisation in ST segment elevation myocardial infarction with multivessel disease. Heart. 2018 Jul; 104(14):1144-1147. Bravo CA, Hirji SA, Bhatt DL, Gluud C, Faxon DP, Ohman EM, Kaneko T, Engstrøm T, Høfsten DE, Brennan JM. PMID: 29439169.
      View in: PubMed   Mentions:
    18. Dual-antiplatelet Therapy Guidelines and Implications for Perioperative Management. J Cardiothorac Vasc Anesth. 2018 Apr; 32(2):1072-1080. Stawiarski K, Kataria R, Bravo CA, Villablanca P, Mohananey D, Narasimhan S, Ramakrishna H. PMID: 29398381.
      View in: PubMed   Mentions:
    19. Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease. Cochrane Database Syst Rev. 2017 May 03; 5(5):CD011986. Bravo CA, Hirji SA, Bhatt DL, Kataria R, Faxon DP, Ohman EM, Anderson KL, Sidi AI, Sketch MH, Zarich SW, Osho AA, Gluud C, Kelbæk H, Engstrøm T, Høfsten DE, Brennan JM. PMID: 28470696; PMCID: PMC6481381.
      View in: PubMed   Mentions:
    20. Response to Letter to the Editor on "Does Vidarabine Mediate Cardioprotection via Inhibition of AC5?". J Pharmacol Exp Ther. 2016 Aug; 358(2):244-5. Bravo CA, Vatner DE, Vatner SF. PMID: 27402380; PMCID: PMC6047221.
      View in: PubMed   Mentions:
    21. A Food and Drug Administration-Approved Antiviral Agent that Inhibits Adenylyl Cyclase Type 5 Protects the Ischemic Heart Even When Administered after Reperfusion. J Pharmacol Exp Ther. 2016 May; 357(2):331-6. Bravo CA, Vatner DE, Pachon R, Zhang J, Vatner SF. PMID: 26941173; PMCID: PMC4851318.
      View in: PubMed   Mentions:
    22. Type 5 adenylyl cyclase increases oxidative stress by transcriptional regulation of manganese superoxide dismutase via the SIRT1/FoxO3a pathway. Circulation. 2013 Apr 23; 127(16):1692-701. Lai L, Yan L, Gao S, Hu CL, Ge H, Davidow A, Park M, Bravo C, Iwatsubo K, Ishikawa Y, Auwerx J, Sinclair DA, Vatner SF, Vatner DE. PMID: 23536361; PMCID: PMC3980473.
      View in: PubMed   Mentions:
    23. Metabolomic analysis of two different models of delayed preconditioning. J Mol Cell Cardiol. 2013 Feb; 55:19-26. Bravo C, Kudej RK, Yuan C, Yoon S, Ge H, Park JY, Tian B, Stanley WC, Vatner SF, Vatner DE, Yan L. PMID: 23127662; PMCID: PMC3980464.
      View in: PubMed   Mentions:
    24. Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase. Am J Physiol Heart Circ Physiol. 2012 Jun 15; 302(12):H2622-8. Iwatsubo K, Bravo C, Uechi M, Baljinnyam E, Nakamura T, Umemura M, Lai L, Gao S, Yan L, Zhao X, Park M, Qiu H, Okumura S, Iwatsubo M, Vatner DE, Vatner SF, Ishikawa Y. PMID: 22505646; PMCID: PMC3378263.
      View in: PubMed   Mentions: